Nicole Pace, MD
Dermatology · Lebanon, NHNPI 1306879804
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,600 of the $5,516 with a category attached, or 65.3%. Lilly USA, LLC accounts for 93.7% of it on its own, with 4 other manufacturers making up the rest.
Across 32 payments — averaging $172.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$5K
- Dermavant Sciences, Inc.$161
- E.r. Squibb & Sons, L.L.C.$94
- Bristol Myers Squibb$80
- Biofrontera Inc.$14
Across 49 payments — averaging $1906.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arcutis Biotherapeutics, Inc.$93K
What the payments were for
- Consulting fees$3,60065%
- Travel & lodging$92217%
- Food & beverage$99318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 27 | $5,166 |
| Dermavant Sciences, Inc. | 2 | $161 |
| E.r. Squibb & Sons, L.L.C. | 1 | $94 |
| Bristol Myers Squibb | 1 | $80 |
| Biofrontera Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,516 in reported general payments places this provider in the 70th percentile of 75 dermatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 15 | $272,151 |
| Tacrolimus | 37 | $4,272 |
| Clobetasol Propionate | 45 | $1,763 |
| Metronidazole | 21 | $1,410 |
| Minoxidil | 120 | $1,120 |
| Spironolactone | 26 | $1,047 |
| Fluorouracil | 12 | $1,006 |
| Ketoconazole | 42 | $678 |
| Finasteride | 44 | $576 |
| Triamcinolone Acetonide | 68 | $568 |
| Minocycline Hcl | 11 | $260 |
| Mupirocin | 20 | $204 |
| Clotrimazole | 12 | $138 |
| Hydrocortisone | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Lebanon
- Yulianna RussakLebanon$170K
- Michael ChapmanLebanon$39K
- Denise AaronLebanon$8K
- Emily ShaughnessyLebanon$6K
- Natalie FragosoLebanon$4K
- Brian SimmonsLebanon$3K
- Elizabeth MarvinLebanon$1K
- Joi CarterLebanon$135
- Chenin RyanLebanon$87
- Alicia DagrosaLebanon$65
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.